MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$115,927K
Net Income
$235K
Net Profit Margin
0.20%
EPS
-$0.02
Unit: Thousand (K) dollars
Revenue Breakdown
us-us-US
europe-europe-Europe
international-international-Inte...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
total revenue
115,927
106,677
104,478
103,693
Cost of revenue from sale of therapies
1,088
434
2,703
513
Research and development expense
73,945
61,113
78,821
70,572
Selling, general and administrative expense
43,890
37,850
42,645
39,779
Income (loss) from operations
-2,996
7,280
-19,691
-7,171
Interest income
3,582
3,418
3,906
4,123
Interest expense
3,062
3,051
3,053
3,043
Foreign currency loss (gain)
-1,108
3,849
-1,460
1,333
Other income, net
3,070
1,776
4,504
5,062
Net income (loss) before income taxes
-514
13,272
-15,794
304
Income tax expense
294
301
14,266
481
Net income (loss)
-808
12,971
-30,060
-177
Exchange differences on translation of foreign operations
1,043
-7,289
1,922
-3,392
Total comprehensive (loss) income
235
5,682
-28,138
-3,569
Basic EPS
-0.02
0.26
-0.556
0
Diluted EPS
-0.02
0.25
-0.577
0
Basic Average Shares
50,973,830
50,754,763
50,598,058
50,403,717
Diluted Average Shares
50,973,830
52,934,787
48,734,944
50,403,717
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Exchange differences on
translation of foreign...
$1,043K
(-83.89%↓ Y/Y)
Total comprehensive
(loss) income
$235K
(106.15%↑ Y/Y)
Net income (loss)
-$808K
(92.16%↑ Y/Y)
Net income (loss)
before income taxes
-$514K
(94.70%↑ Y/Y)
Income tax expense
$294K
(-51.49%↓ Y/Y)
Interest income
$3,582K
(-16.13%↓ Y/Y)
Other income, net
$3,070K
(-34.58%↓ Y/Y)
us-us-US
$74,937K
(16.93%↑ Y/Y)
europe-europe-Europe
$34,124K
international-international-International
$6,866K
Interest expense
$3,062K
(0.56%↑ Y/Y)
Income (loss) from
operations
-$2,996K
(79.86%↑ Y/Y)
total revenue
$115,927K
(18.34%↑ Y/Y)
Foreign currency loss
(gain)
-$1,108K
(-50.14%↓ Y/Y)
Research and development
expense
$73,945K
(7.15%↑ Y/Y)
Selling, general and
administrative expense
$43,890K
(2.57%↑ Y/Y)
Cost of revenue from
sale of therapies
$1,088K
(4.62%↑ Y/Y)
Buy us a coffee
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)